GMABGenmab A/S
Price
+31%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, growth fading, the market undecided.
We are an international biotechnology company with a pipeline of novel antibody-based products and product candidates designed to address medical needs and improve treatment outcomes for patients with cancer and other serious diseases. Our goal in building our pipeline is to bring medicines to market ourselves in geographic areas where we believe we will be able to maximize their value and make a meaningful impact on the treatment landscape.
In the company’s own words · 20-F filed Feb 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Genmab A/S (GMAB) reported revenue of DKK 12.0B in H2 2024 (quarter ended Dec 31, 2024), up 187% from the same quarter a year earlier. That came with a gross margin of 95% and net income of DKK 5.11B (43% of revenue). For the full year FY2024, revenue was DKK 21.5B (+31% year on year) and net income DKK 7.84B.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.